Skip to main content
. 2020 Oct 28;68(12):2735–2743. doi: 10.1111/jgs.16894

Table 1.

Clinical Characteristics of Patients

Characteristic Total (N = 76) Survivors (N = 54) Nonsurvivors (N = 22) P value
Age, y 90 (86–92) 90 (86–92) 89.50 (86–95) .831
Male sex 34 (44.7) 19 (35.2) 15 (68.2) .011
BMI, kg/m2 22.6 (19.6–25.4) 22.6 (19.5–24.8) 23.4 (20.9–26.12) .394
Malnutrition 29 (38.2) 23 (42.6) 6 (27.3) .298
Obesity (BMI > 30 kg/m2) 2 (2.6) 1 (1.9) 1 (4.5) .498
Clinical Frailty Score 6 (5–7) 6 (5.7–7) 6 (5–7) .111
Patient origin .130
Home 35 (46.0) 21 (38.9) 14 (63.6)
Long‐term care facility 24 (31.6) 20 (37.0) 4 (18.2)
Hospital 17 (22.4) 13 (24.1) 4 (18.2)
Comorbidities .432
0 2 (2.6) 1 (1.9) 1 (4.6)
1–2 25 (32.9) 20 (37.0) 5 (22.7)
>2 49 (64.5) 33 (61.1) 16 (72.7)
Medical history
Cardioneurovascular diseases 35 (46.1) 20 (37.0) 15 (68.2) .013
Arterial hypertension 62 (81.6) 45 (83.3) 17 (77.3) .531
Coronary artery disease 15 (19.7) 8 (14.8) 7 (31.8) .116
Cardiac insufficiency 24 (31.6) 19 (35.2) 5 (22.7) .416
History of thrombosis 9 (11.8) 9 (16.7) 0 (0.0) .052
COPD 6 (7.9) 4 (7.4) 2 (9.1) 1.000
Respiratory insufficiency 5 (6.6) 4 (7.4) 1 (4.5) 1.000
History of stroke 22 (28.9) 17 (31.5) 5 (22.7) .580
Cognitive impairment 48 (63.2) 38 (70.4) 10 (45.5) .055
Neurodegenerative disease 13 (17.1) 7 (13.0) 6 (27.3) .180
Chronic kidney disease 20 (26.3) 11 (20.4) 9 (40.9) 1.000
Diabetes mellitus 13 (17.1) 7 (13.0) 6 (27.3) .180
Malignancy 10 (13.2) 9 (16.7) 1 (4.5) .265
History of fall 19 (25.0) 15 (27.8) 4 (18.2) .560
Treatment
Beta‐blocker 26 (34.2) 18 (33.3) 8 (36.4) .796
Angiotensin‐renin system inhibitors 19 (25.0) 13 (24.1) 6 (27.3) .777

Note: Data are median (interquartile range) or number (percentage). P < .05 indicates significant difference between survivors and nonsurvivors.

Abbreviations: BMI, body mass index; COPD, chronic obstructive pulmonary disease.